• search
For Quick Alerts
For Daily Alerts

Most anticipated COVID-19 drug, remdesivir cleared for use in severe cases


New Delhi, June 02: The use of anti-viral medication, remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 cases has been cleared by India's top drug regulatory body.

One of the most closely watched drugs in the global clinical trials, remdesivir was approved by the Drug Controller General of India for administration as part of a maximum five day regimen, reports say.

Most anticipated COVID-19 drug, remdesivir cleared for use in severe cases
    WHO says Sars-Cov-2 is still a killer virus, rejects 'losing potency' claim | Oneindia News

    The drug is manufactured by the American biopharma giant, Gilead Sciences. It would be imported by the Mumbai based Klineria Global Services from the manufacturing sites of Gilead.

    Remdesivir improves time to recovery in COVID-19 patients: Study

    Reports also say that the Central Drugs Standard Control Organisation has decided against extending the use of the drug to 10 days, based on existing evidence presented to it at the time of approval.

    The approval now paves the way for generic voluntary licence holders in the country to manufacture the drug. An Indian Express report said that the restriction of the drug to five days will save patients a lot of money.

    For Daily Alerts
    Get Instant News Updates
    Notification Settings X
    Time Settings
    Clear Notification X
    Do you want to clear all the notifications from your inbox?
    Settings X
    We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more